44 related news articles for Ovarian cancer

There are few parts of the Australian community that remain untouched by ovarian cancer. The team at Spotlight Group Holdings, one of the nation’s largest retail organisations, is supporting Hudson Institute’s work to help find a cure and better early diagnostics for the deadly disease.…  Read more

Their latest research, published in the esteemed journal, Nature, showed that the innate immune system produces a powerful weapon against ovarian cancer – interferon epsilon (IFNe) – a weapon just waiting to be harnessed to deliver an effective immunotherapy treatment option.…  Read more

For Associate Professor Simon Chu, the problem leading Hudson Institute’s research into rare ovarian cancers was getting access to large quantities of real-world data, and the solution came from a surprising place: social media.…  Read more

Director’s Message: Changing the odds on ovarian cancer. As medical researchers, we spend a lot of our time looking at numbers, establishing which changes or effects are significant and which are not.…  Read more

Jessica Clark calls herself the luckiest unlucky person in the world – but she still wants to know why she got ovarian cancer at such a young age.…  Read more

In medical research, the path from laboratory bench to patient bedside is usually a very long one. And when it comes to breakthroughs in specific testing for ovarian cancer, it is a path that no-one has yet navigated successfully.…  Read more

In a distinguished scientific career lasting four decades, Professor Paul Hertzog has just about seen it all – but seeing his team’s latest research published in the influential journal Nature was a proud moment.…  Read more

When it comes to rare forms of cancer, researchers and patients share the same problem – finding enough information from which to make informed decisions.…  Read more

A new blood test is now being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients and the healthcare system.…  Read more

The search for preventions and cures has turned inward – focussing on the immune system to stop ovarian cancer.…  Read more

Exciting new treatments for unmet medical needs including ovarian cancer have been awarded significant funding from Australia’s national biotechnology incubator, CUREator.…  Read more

Six of the best early career researchers have been chosen to take part in the Hudson Institute 2023 Emerging Leaders Program. …  Read more

Ovarian cancer specialists have taken a novel path to advance their research – tapping into an international Facebook group to learn from members’ experiences.…  Read more

Not even Covid-19 could stop a pioneer in the fight against rare ovarian cancers finishing his epic fundraising ride. In early May Dr Simon Chu took a break from the lab and put rubber on the road in the Ride4Research, aiming to cover 900km in 9 days from Canberra to Melbourne.…  Read more

On 16 March we were delighted to welcome a group from Fire Rescue Victoria, who are generously supporting our research into the BRCA1 or BRCA2 mutations via the Firefighters Charity Fund. …  Read more

A pioneer in the fight against rare ovarian cancers is taking a break from the lab and putting rubber on the road as part of the Ride4Research.…  Read more

Seeing their baby diagnosed with a rare ovarian cancer before her first birthday instantly made one Central Victorian family advocates for medical research.…  Read more

Hudson Institute of Medical Research is proud to be a recipient in the latest round of funding from the Ovarian Cancer Research Foundation (OCRF).…  Read more

Hudson Institute researchers have shown for the first time that a diabetes drug called sitagliptin can limit tumour growth, and possibly extend survival rates from epithelial ovarian cancer, the most common and dangerous type of ovarian cancer.…  Read more

Hudson Institute has been successful in the NHMRC Ideas Grant round. Our researchers have been awarded four NHMRC Ideas Grants, totalling almost $4.1 million.…  Read more

Women with a rare and potentially aggressive form of ovarian cancer will benefit from a grant to continue ground-breaking research into new detection and treatment methods.…  Read more

Researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer.…  Read more

Five Hudson Institute researchers have been awarded one-year Medicine/Science grants totalling nearly $300,000 by The CASS Foundation, to advance their research projects into mitochondrially-driven cancers, ovarian cancer, Parkinson’s disease, primary aldosteronism and endometriosis in 2020.…  Read more

For the month of ‘frocktober’ ovarian cancer researchers, Dr Maree Bilandzic and Dr Amy Wilson swapped their white lab coats for colourful frocks as part of the Frocktober campaign to raise funds and awareness for ovarian cancer research.…  Read more

Highly mobile, invasive ovarian cancer cells called ‘leader cells’ have been discovered as the cells that lead the attack on healthy tissue.…  Read more

A group of 26 students from Ivanhoe Girls’ Grammar School have fundraised to create the school’s inaugural Early Career Ovarian Cancer Research Travel Award, which has been awarded to Hudson Institute’s own Dr Amy Wilson.…  Read more

Reproductive health research leader Professor Jock Findlay AO has been elected a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS), acknowledging his significant achievements in reproductive health research.…  Read more

Dr Bilandzic, an ovarian cancer researcher, has been awarded $700,000 for research into deadly ovarian cancer cells called ‘leader cells’, which can survive and even thrive in response to cancer treatment. …  Read more

Two Hudson Institute researchers, Dr Jun Yang and Dr Maree Bilandzic have been successful in the 2019 IMPACT Philanthropy program, from Perpetual, which are awarded to organisations based on their strategy, outcomes, capability and leaderships.…  Read more

Ovarian cancer is responsible for more deaths than any other gynaecological disease, yet it’s known as the ‘silent killer’, due to an absence of symptoms and a devastatingly low survival rate of less than 50 per cent. Our leading ovarian cancer researchers are progressing solutions to help these women – thanks to support from the…  Read more

A double-barrelled, non-surgical method to treat a rare type of ovarian cancer may provide hope for many patients.…  Read more

Ovarian cancer research leaders from across Australia met at Hudson Institute of Medical Research on Thursday, 15 November, for a new research symposium focused on progressing solutions to the disease.…  Read more

A new study has identified a genetic mutation that could be linked to an aggressive type of ovarian cancer driven by hormones. A team of scientists at Hudson Institute of Medical Research, with collaborators at the Peter MacCallum Cancer Centre and the University of Western Australia, used large-scale genome sequencing to map the tumour genome…  Read more

A clinical trial of a screening test developed by Hudson Institute scientist, Dr Andrew Stephens to detect ovarian cancer in its early stages is about to start in a large group of Victorian and South Australian women, thanks to funding from the Ovarian Cancer Research Foundation (OCRF). About 300 women will be recruited to the…  Read more

Hudson Institute and School of Clinical Sciences PhD student, Aidan Kashyap has taken out second prize in Monash University’s Faculty of Medicine, Nursing and Health Sciences Three Minute Thesis (3MT) Competition. Aidan’s research is finding therapies to help babies who struggle to breathe in their first moments of life due to underdeveloped lungs, as a…  Read more

The Active Ratio Test represents an exciting step forward in innovative ovarian cancer research. Should it be successful, a test as simple as taking a swab or blood sample will result in the early detection of ovarian cancer in women who otherwise exhibit no symptoms. Vague and misleading symptoms, combined with the need for invasive…  Read more

‘Off-the-shelf’ immunotherapies to fight aggressive forms of cancer, including relapsed ovarian and gastric cancers, are being developed in Clayton, Melbourne, thanks to almost $3 million in Federal Government funding awarded to lead participant Cartherics Pty Ltd. Hudson Institute of Medical Research and Monash University researchers are partnering with industry leaders in cell therapies to develop…  Read more

Precision medicine is providing new hope for patients with ovarian cancer, the most common cause of death from gynaecological cancers. Only 3 out of every 10 women diagnosed with advanced stage ovarian cancer will survive after five years. These statistics haven’t improved in 30 years, but precision medicine approaches are opening up new possibilities. While…  Read more

Hudson Institute has entered into a Research and Development Alliance Agreement with Invion Limited to provide key scientific assessment of Invion’s cancer treatment technology, Photosoft. The collaboration will initially focus on the treatment of ovarian cancer, with a view to expanding research and development projects into other forms of cancer. Hudson Institute will provide the…  Read more

The inaugural Dr Sue Fowler Scholarship in Ovarian Cancer has been awarded to PhD student, Mrs Nazanin Karimnia to support her research into new ovarian cancer therapies. The scholarship was established in honour of the late Dr Sue Fowler, to support a Hudson Institute PhD student undertaking research into ovarian cancer. There is an urgent…  Read more

Hudson Institute’s brightest scientific minds and most promising discoveries will be progressed, thanks to support from a leading philanthropist, Mr Peter Fielding and the Fielding Foundation. The 2018 Fielding Innovation Award has been awarded to Dr Maree Bilandzic to develop more effective treatments for women with ovarian cancer. The 2018 Fielding Foundation Fellowship has been…  Read more

Scientists at Hudson Institute are closer to developing an early detection test for ovarian cancer and better therapies to treat the disease, thanks to new research funding. The Ovarian Cancer Research Foundation (OCRF) has generously announced $1.4 million in grants, including funding for research projects at Hudson Institute and a grant to maintain a vital…  Read more

A new study by Hudson Institute of Medical Research and Fiona Elsey Cancer Research Institute scientists has uncovered important differences between pre- and post- chemotherapy ovarian cancer tumours that may be used to better tackle chemotherapy resistance.…  Read more

Hudson Institute researchers Dr Simon Chu and Dr Andrew Stephens have been awarded grants totalling more than $700,000 over three years by the Ovarian Cancer Research Foundation (OCRF),  to support ongoing work to improve early-stage tumour detection and to develop better therapies for women with ovarian cancer.…  Read more